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Introduction
Frontotemporal lobar degeneration, progressive supranuclear 
palsy (PSP), and corticobasal degeneration (CBD) have over-
lapping clinical and pathological features. PSP is a clinico-
pathological entity that typically presents as an akinetic rigid 
syndrome with early postural instability, axial rigidity, and vari-
able supranuclear gaze palsy. In particular, supranuclear verti-
cal gaze palsy, moderate or severe postural instability, and falls 
during the first year after onset are the main characteristics of 
PSP and they affect the accuracy of the clinical diagnosis (9% 
error according to logistic regression).
1,2 We report a patholog-
ically confirmed case of PSP that presented with behavioral 
changes including agitation and irritability, which eventually 
progressed to cardinal symptoms, such as frequent falls and su-
pranuclear gaze palsy.
Case Report
In 2004, a 52-year-old Korean woman was evaluated for sleep 
disturbance and behavioral changes over the previous two 
years. She walked around her neighborhood all day, meddling 
in other people’s affairs and starting arguments with them. Her 
neighbors did not want to spend time with her, and her inap-
propriate behavior was worsening progressively. She visited a 
psychiatry clinic initiated by her husband, and was diagnosed 
with severe anxiety neurosis of unknown etiology. She was pre-
scribed medicines for her insomnia and behavioral problems, 
but her symptoms worsened. Her husband reported that her 
memory had been impaired for 6 months before her first visit 
to us. 
Her past medical and family histories were unremarkable. 
She graduated from high school and then worked as a secre-
tary for a small company until she got married. She was a very 
kind and careful housewife. 
On neurological examination, she was alert and oriented. 
However, she could not stay seated in a chair for more than a 
few minutes, instead walking around the outpatient clinic. Her 
speech was fluent and cranial nerve examinations produced 
normal results. The motor and sensory examinations were un-
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remarkable. She complained of mild lower back pain but no 
gait disturbance. 
She scored 23/30 on the Korean version of the Mini-Mental 
Status Examination
3 and had a clinical dementia rating
4 of 0.5. 
The Neuropsychiatric inventory
5 revealed agitation, irritabil-
ity, and disinhibition, and her husband reported her sleep dis-
order. Her behavioral symptoms prevented the application of 
detailed neuropsychological tests because of her behavioral 
symptoms. The laboratory data, including thyroid function 
tests, were normal. Brain magnetic resonance imaging (MRI) 
showed diffuse atrophy changes (Fig. 1A) and brain 
18F-fluoro-
deoxyglucose positron emission tomography (18F-FDG PET) 
revealed subtly decreased glucose metabolism in the right pre-
frontal and both posterior frontal areas (Fig. 1B). 
We diagnosed this patient with a behavioral variant of 
frontotemporal dementia at that time. Six months later, she re-
turned to our hospital due to severe lower back pain and gait 
disturbance. She underwent lumbar MRI in the orthopedic 
clinic, but no specific abnormalities were detected. Neurolog-
ical examinations revealed mild features of Parkinson’s disease. 
Her facial expression was slightly decreased and her speech 
was monotonous compared to at the previous examoination. 
She had no tremor, but showed bradykinesia and mild symmet-
ric rigidity. Limb apraxia and alien hand syndrome were not re-
vealed. Her gait was short-stepped and slightly festinating, 
but without postural instability. Her extraocular movements 
showed no definite abnormalities. Our working diagnosis was 
FTD with parkinsonism. We requested a genetic study for FTD 
and parkinsonism linked to chromosome 17 (FTDP-17), but 
this did not reveal a genetic mutation of microtubule associat-
ed protein tau. 
We prescribed the maximum allowable doses of the dopami-
ne agonist and L-dopa, but thios resulted in her symptoms wa-
xing and waning, rather than improving decisively. She grad-
ually developed walking hesitation and was prone to falling. 
Vertical gaze limitation was observed in a neurological exam-
ination. We performed follow-up brain MRI and 
18F-FDG PET 
studies. The brain MRI showed marked bilateral temporal and 
midbrain atrophy with ventricular dilatation, with the changes 
being greater in the right temporal lobe than in the left tempo-
ral lobe (Fig. 2A). Brain 
18F-FDG PET revealed decreased glu-
cose metabolism in the bilateral frontotemporal and parietal ar-
eas, with the decrease being in the right temporal lobe than in 
the left temporal lobe (Fig. 2B). 
We made a diagnosis of probable PSP based on the Nation-
al Institute of Neurological Disorders and Stroke and the Soci-
ety for PSP Criteria.
1 The patient started to develop difficulty 
swallowing and dysarthria, and these symptoms deteriorated 
relentlessly. Eventually, she became bedridden and required re-
spiratory support with mechanical ventilation. Her family 
wanted confirmation of the diagnosis of her progressive disease, 
so we performed a brain biopsy and pathological evaluation. 
The biopsy of the temporal and frontal cortices showed tau-pos-
itive neurons (Fig. 3A) and reactive gliosis with tufted astrocy-
tes (Fig. 3B).
Fig. 1. A: Brain magnetic resonance im-
aging shows diffuse brain atrophy on flu-
id-attenuated inversion recovery  imag-
es. B: Brain 
18F-fluorodeoxyglucose posi-
tron emission tomography reveals subtly 
decreased glucose metabolism in the 
right prefrontal and both posterior frontal 
areas.  A   B  
Fig. 2. A: Brain MRI shows marked bi-
lateral temporal and midbrain atrophy 
with ventricular dilatation that is worse 
in the right temporal lobe than in the left 
temporal lobe on fluid-attenuated inver-
sion recovery images. B: Brain 
18F-fluo-
rodeoxyglucose positron emission to-
mography reveals decreased glucose 
metabolism in the bilateral frontotem-
poral and parietal areas, with the de-
crease being in the right temporal lobe 
than in the left tempopral lobe. A   B  Behavioral Changes in Progressive Supranuclear Palsy
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Discussion
Most published reports on the behavior of patients with PSP 
emphasize symptoms related to depression or apathy, while 
psychotic or obsessive features are rarely described. Litvan et 
al.
6 investigated the behavioral symptoms of PSP, Alzheim-
er’s disease, and controls using the NPI and noted that apathy 
was the most frequent behavioral abnormality; moreover, the 
presence of high apathy and low agitation scale scores cor-
rectly identified the patients with PSP. 
In contrast, in our case, agitation and disinhibition were the 
earliest and most prominent behavioral symptoms. As shown 
previously, apathy and disinhibition are associated with pro-
gressive dysfunction of different subcortical circuits and do 
not proceed in parallel, and neuropsychiatric disorders are in-
dependent of cognitive dysfunction. 
Five frontal-subcortical circuits unite regions of the frontal 
lobe with the striatum, globus pallidus, and thalamus, in func-
tionally mediating motor activities, eye movements, cognition, 
and behavior. The five circuits originate in the supplementary 
motor area, frontal eye fields, dorsolateral prefrontal cortex, or-
bitofrontal cortex, and anterior cingulate cortex, which respec-
tively mediate volitional motor activities, saccadic eye move-
ments, executive functions, social behavior, and motivation. All 
five of these circuits are affected in PSP, with corresponding 
functional and behavioral abnormalities being evident. Apathy 
is associated with dysfunction of the medial frontal-subcortical 
circuits and disinhibition is the behavioral correlate of the 
orbitofrontal-subcortical circuitry.
6,7 
We believe that the orbitofrontal cortex, rather than the me-
dial frontal cortex, was initially involved in our patient because 
her behavioral symptoms of agitation and disinhibition devel-
oped very early in her disease. The initial brain PET showed 
decreased glucose metabolism at right prefrontal and both pos-
terior frontal cortices. To the best of our knowledge, agitation 
or disinhibition as an initial symptom of PSP is very rare, al-
though psychosis has been reported as the presenting symptom 
in PSP in a few cases.
8
PSP is a common cause of atypical parkinsonian syndrome 
with dementia. However, the diagnosis of PSP can be a diffi-
cult one, and both false-positive and false-negative misdiag-
noses may occur. Pathologically confirmed cases of cardiovas-
cular disease, diffuse Lewy body disease, multiple system atro-
phy, CBD, subcortical gliosis, Pick’s disease, Whipple’s disease, 
neurosyphilis, and prion disease have all been clinically misdi-
agnosed as PSP.
9 In fact, we initially diagnosed our case as FTD 
before the parkinsonian features did developed. Moreover, al-
though parkinsonian features developed, we believed that she 
had FTD-P-17 and did not consider PSP because the clinical hall-
marks such as a falling tendency or supranuclear gaze abnor-
mality were not evident at that time. Litvan et al.
1 noted that sev-
eral features should raise suspicion of PSP, including early in-
stability and falls and vertical supranuclear palsy particularly 
during the first year of symptom onset. 
Williams et al., recently noted that pathologically confirmed 
cases show two clinical phenotypes based on factor analysis, 
which they named Richardson’s syndrome and PSP-parkin-
sonism (PSP-P). RS, like classical PSP, is characterized by ear-
ly-onset postural instability and falls, supranuclear gaze palsy, 
and cognitive decline. Conversely, PSP-P initially presents with 
parkinsonian features and is frequently confused with Parkin-
son’s disease. They proposed that PSP-P represented a distinct 
clinical phenotype because different tau isoform deposition 
was seen in the basal pons, and this needs to be distinguished 
clinically from classical PSP.
10 Based on previous reports and 
our case, gait instability and gaze abnormality are not absolute 
requirements as presenting symptoms for a diagnosis of prob-
able PSP, and the initial clinical diagnosis criteria are not man-
datory. 
The tau-positive neurodegenerative diseases are character-
ized by tau-positive inclusions and include PSP, CBD, Pick’s 
disease, multiple system atrophy, and FTDP-17.
11 However, 
tauopathy-neurodegenerative diseases present some unique 
histopathologic features. Focal asymmetric cortical atrophy 
with ballooned neurons, nigral degeneration and astrocytic 
plaques in the affected cortex are characteristic features of 
CBD. On the other hand, the distinctive cytopathologic find-
Fig. 3. Brain biopsy of the temporal and 
frontal cortices. The immunohistochem-
ical staining for (A) tau and (B) glial fibril-
lary acidic protein shows tau-positive 
globose tangles (×400) and reactive glio-
sis with tufted astrocytes (×400). A   B  Han HJ et al.
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ings of PSP are globose-type neurofibrillary tangles in the 
brainstem, and substantia nigra, and tufted astrocytes, which 
are abundant in the precentral gyrus and striatum.
12 The 
pathologic results in our case revealed globose tau-positive 
neurons and tufted astrocytes, which are findings more spe-
cific to PSP, but not astrocytic plagues and ballooned neu-
rons. Therefore, we consider that the pathological findings 
supported a diagnosis of PSP, but not CBD or FTDP-17 even 
though biopsy specimens were taken from the frontal and 
temporal cortices. We have reported here in the case of a pa-
tient who presented with unusual behavioral symptoms, along 
with her clinical course with pathological data.
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